-
Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomized controlled trial
-
Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors
-
Response of a chemo-resistant triple-negative breast cancer patient to a combination of p62-encoding plasmid, Elenagen, and CMF chemotherapy
-
P62-DNA-encoding plasmid reverts tumor grade, changes tumor stroma, and enhances anticancer immunity
-
Broad-spectrum Anti-tumor and Anti-metastatic DNA Vaccine based on p62-encoding Vector
-
Pilot Study of p62 DNA Vaccine in Dogs with Mammary Tumors
-
p62/SQSTM1 indirectly mediates remote multipotent mesenchymal cells and rescues bone loss and bone marrow integrity in ovariectomized rats
-
P62/SQSTM1 enhances osteogenesis and attenuates inflammatory signals in bone marrow microenvironment
-
Plasmid DNA-coding p62 as a Bone Effective Anti-inflammatory/Anabolic Agent
-
P62 plasmid can alleviate diet-induced obesity and metabolic dysfunctions
-
p62 /SQSTM1 coding plasmid prevents age related macular degeneration in a rat model
-
p62 / SQSTM1 Expression In Canine Mammary Tumours: Evolutionary Notes
-
Neuroprotective effects of p62(SQSTM1)-engineered lactic acid bacteria in Alzheimer’s disease: a pre-clinical study
-
P62/SQSTM1 beyond Autophagy: Physiological Role and Therapeutic Applications in Laboratory and Domestic Animals
